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Abstract. Inflammatory bowel diseases (IBD) represent a group of chronic conditions of the gastrointestinal 
tract of unknown etiology. Latest knowledge accentuates the bidirectional connection between the central and 
enteric nervous systems. An important role of peptidases has been proposed in maintaining the homeostasis 
in the gut. One of them is dipeptidil-peptidase IV (DPP IV/CD26), a multifunctional glycoprotein found in 
both soluble and membrane-bound form in living organisms. In order to evaluate the relevance of DPP 
IV/CD26 among the gut-brain axis, a TNBS (Crohn-like) model of colitis has been induced in CD26 defi-
cient and wild type mice. Results of this study showed that CD26 deficient mice show specificity in histolog-
ical damage compared to wild type mice. A decreased DPP IV/CD26 activity was found in serum, colon and 
brain in wild type mice with colitis, while CD26 protein expression was increased in colon of those mice. 
DPP IV/CD26-like activity was decreased only in colon of CD26 deficient mice. Changes occurring during 
inflammatory processes in colon reflected on investigated parameters in brain. Therefore, our results indicate 
the importance of the gut-brain axis in the pathogenesis of IBD. (doi: 10.5562/cca1813)  
Keywords: dipeptidyl-peptidase IV, CD26 molecule, CD26 deficient mice, inflammatory bowel diseases, 
TNBS-colitis, gut-brain axis  
 
INTRODUCTION 
Inflammatory bowel diseases (IBD) represent a group of 
idiopathic, chronic inflammatory conditions that could 
affect different segments of the gastrointestinal tract, 
with numerous complications and extraintestinal mani-
festations.1 Two main pathomorphological entities  
of IBD are Crohn's disease (CD) and ulcerative colitis 
(UC), sharing some similarities, but also having indi-
vidual characteristics in disease manifestations. The 
etiology of IBD, despite of many investigations, still 
remains unknown.2 It is generally accepted that IBD 
occurs in genetically susceptible individuals, under 
influence of environmental and microbiological fac- 
tors, as an overexpressed immunological response  
to antigens of unknown origin.3 Latest knowledge  
regarding IBD pathogenesis includes the influence of 
neuroimmunological parameters, which are driven  
by the hypothesis that neurogenic inflammation could  
be involved in inflammatory processes in the gut.4  
Given the connection of enteric and central nervous 
system and the bidirectional communication between 
the gut and the brain, a term "gut-brain-axis" has been  
introduced and proposed as an important aspect in the  
etiology of IBD.5 
In order to elucidate the pathogenesis of IBD, dif-
ferent animal models of gastrointestinal inflammation 
have been developed.6 One of the most accepted exper-
imental model of Crohn-like-colitis is the 
trinitrobenzenesulfonic acid-induced (TNBS) colitis, 
which resembles many histological, immunological and 
clinical manifestations of CD in humans.7 Animal mod-
els of IBD have given insight in different processes at 
the molecular level which lead to development of in-
flammatory changes and have revealed the importance 
of many molecules involved in IBD etiology.8  
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In the last decade, proteases have been proposed 
as important factors in inflammatory processes, given 
their ability to metabolize different biologically active 
substrates involved in maintaining the integrity of the 
mucosal barrier.9 One of them is dipeptidyl-peptidase 
IV, known also as CD26 molecule (DPP IV/CD26). 
DPP IV/CD26 is a highly glycosylated type II 
transmembrane sialoglycoprotein comprising two iden-
tical subunits of approximately 110 kDa.10 DPP 
IV/CD26 was originally characterized as a T-cell differ-
entiation antigen and was reported to be expressed on 
various cell types, having multiple functions in various 
biological processes, including immunological regula-
tions.11 A soluble form circulating in body fluids is 
found in living organisms. As a serine protease, it pos-
sesses a specific peptidase function with unique features 
in substrate processing: it cleaves dipeptides from the 
N-terminus of polypeptides where proline or alanine is 
at the penultimate position. Since N-termini containing 
Xaa-Pro are not easily cleaved by other proteases, the 
action of DPP IV/CD26 is a rate-limiting step in the 
degradation of many polypeptides.12 
Different cytokines, chemokines and neuropep-
tides involved in inflammatory events are found among 
DPP IV/CD26 substrates.13 Our hypothesis was that 
CD26 deficient mice would express differences in in-
flammatory processes and disease manifestations. This 
study was undertaken in order to have an insight in 
histological and biochemical alterations at local and 
systemic levels during development and resolution of 
colitis under conditions of DPP IV/CD26 deficiency in 
comparison with wild type mice. Furthermore, we 
wanted to evaluate changes in DPP IV/CD26 and DPP 
IV/CD26-like activity at local and systemic levels, 
likewise DPP IV/CD26 protein expression in targeted 
tissues during colitis development and resolution. Given 
the potential importance of the gut-brain axis in the 
development of inflammatory processes, experiments 
were focused on changes occurring at local site of in-
flammation - in colon, and in the central nervous system 




This study was performed using two mice strains: wild 
type mice strain C57BL/6 and mice with inactivated 
gene for molecule CD26 (C57BL/6 Jbom-ob, CD26–/–), 
generated on a C57BL/6 genetic background. CD26 
deficient mice were kindly provided by Dr. Didier 
Marguet, Centre d’Immunologie Marseille-Luminy, 
France. Generation of CD26 deficient mice has been 
described previously.14 Male, 8–10 week old mice were 
used in this study. Animals were housed and bred under 
standard conditions at the Central Animal Facility of the 
School of Medicine, University of Rijeka. Laboratory 
animals were housed in plastic cages, fed with standard 
pellet food (MK, Complete Diet for Laboratory Rats 
and Mice, Slovenia) and given tap water ad libitum. 
They were maintained under a 12/12 hours dark/light 
cycle at constant temperature (20 ± 1) °C and humidity 
(50 ± 5) %. Each study group comprised 8–10 animals. 
Animal handling, experimental procedures and anesthe-
sia were performed in accordance with the general prin-
ciples contained in the Guide for the Care and Use of 
Laboratory Animals (National Academic Press). The 
Ethical Committee of the School of Medicine, Universi-
ty of Rijeka, approved all experimental procedures. 
 
Colitis Induction 
Crohn-like-colitis (TNBS-colitis) was induced by rectal 
administration of 5 % (mass concentration) 2,4,6-tri- 
nitrobenzenesulfonic acid solution (TNBS, Sigma-
Aldrich, Germany) dissolved in 50 % ethanol (Kemika, 
Croatia). Each animal received 0.1 mL of TNBS-
ethanol solution, using a vinyl catheter that was posi-
tioned 4 cm from the anus, as described previously.7 
Two control groups of mice were used for each mice 
strain. Control mice underwent identical procedures, but 
were instilled equal volumes of saline (NaCl, γ = 0.9 %) 
or ethanol solution. Administration of TNBS, saline or 
ethanol solution was performed in mice anesthetized 
with ketamine/xylazine.  
 
Experimental Procedures 
Animals were sacrificed by cervical dislocation after 2, 
7, 15 and 30 days upon administration of TNBS, saline 
or ethanol solution. Peripheral blood samples were tak-
en and serum samples were collected by centrifugation 
at 3000 rpm for 10 minutes. Colons were freed from 
adhering tissue and macroscopic changes were noted. 
The colon lumen was carefully washed with ice-cold 
saline and its weights and lengths was measured. One 
part of the colon was used for histological analyses 
while the remaining segments of the colon were slit 
open longitudinally and the mucosa was scraped using a 
glass microscope slide. Colonic mucosal samples were 
prepared from obtained mucosal scrapings according to 
Ahnen et al.15 Obtained mucosal aliquot samples were 
stored at –80 °C until further analyses. 
Brains were separated immediately after sacrifice, 
washed in ice-cold saline and frozen in liquid nitrogen 
then stored at –80 °C until further analyses. Brains were 
homogenized on ice in a volume of 0.4 mL of 0.1 M 
TRIS-HCl buffer (pH = 8). Homogenates were then 
centrifuged at 14000 rpm for 20 minutes at +4 °C. Result-
ing supernatants were measured for total protein concen-
trations according to the method of Bradford et al.16 
L. Batičić Pučar et al., DPP IV/CD26 in Experimental Colitis 203 
Croat. Chem. Acta 85 (2012) 201. 
Histological Analyses  
Colon tissues were collected and fixed in 4 % formalin 
for 24 h. Samples were processed and embedded in 
paraffin wax. Two-micrometer sections were stained 
with hematoxylin and eosin for histological analyses. 
An experienced pathologist blinded to treatment alloca-
tion scored microscopical changes, including overall 
severity of damage, number of crypts of Lieberkühn and 
their depth and width. Microscopic analysis was carried 
out using an Olympus BX40 microscope (Tokyo, Japan) 
and the Pulnix TMC 76S digital camera (Tokyo, Japan). 
Analyses of digital images were performed using Issa 
software package (VAMS, Zagreb, Croatia).  
 
DPP IV/CD26 Activity Assay 
The DPP IV/CD26 (in C57BL/6) and DPP IV/CD26-
like enzymatic activities (in CD26 deficient mice) in 
serum, brain and colon homogenates were measured 
according to the protocol of Kreiser et al.17 by detection 
of free 4-nitroaniline in an assay mixture containing  
0.1 M Tris-HCl buffer (pH = 8), and 2 · 10–3 M Gly-Pro 
p-nitroanilide as the substrate (Sigma-Aldrich, Germa-
ny) in a total volume of 0.20 mL. The reaction was 
stopped by addition of 0.80 mL of sodium acetate buffer 
(1 mol dm–3, pH = 4.5) after 30 minutes of incubation at 
37 °C. The amounts of hydrolyzed substrate were meas-
ured in duplicates spectrophotometrically at λ = 450 nm 
using a Varian Cary UV/Vis Spectrophotometer. En-
zyme activities are expressed according to the Nomen-
clature Committee of the International Union of Bio-
chemistry. Serum DPP IV/CD26 and DPP IV/CD26-
like enzyme activities are expressed as amount of sub-
strate hydrolyzed per liter of serum (nkat L–1). DPP 
IV/CD26 and DPP IV/CD26-like enzyme activities in 
brain and colon homogenates are expressed as the 
amount of substrate hydrolyzed per mg of protein (nkat 
mg–1 of protein).  
 
CD26 Western Blot Analysis  
Brain and colon samples for Western blot analyses of 
CD26 protein expression were homogenized on ice 
using RIPA lysis buffer including inhibitors of proteases 
and phosphatases (Santa Cruz Biotechnology Inc., CA). 
Homogenates were then centrifuged at 14000 rpm for 
20 minutes at +4 °C. Resulting supernatants were meas-
ured for total protein concentrations according to the 
method of Bradford et al.16 All samples were heated for 
5 min at 95 °C in a sample buffer. Prestained molecular 
weight markers (Kaleidoscope Prestained Standards, 
BIO-RAD and Fermentas Life Sciences PageRulerTM) 
were used as standards. Equal amounts of total proteins 
(50 μg per lane) were separated by sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis on 10 % gels. 
Samples were electrophorezed at 50 V for 6 h on ice. 
Proteins were transferred from the polyacrylamide gels 
to polyvinylidenedifluoride membranes by 
electroblotting in a semi-dry transfer apparatus at 0.22 
mA for 45 min. Membranes were blocked for 2 hours at  
4 °C in phosphate-buffered saline containing 0.05 % 
Tween 20 (PBS-T, Amersham Biosciences, USA), con-
taining 5 % (mass concentration) nonfat milk powder 
(Santa Cruz Biotechnology Inc., CA). Membranes were 
treated overnight with primary anti-CD26 antibody 
(Santa Cruz Biotechnology Inc., CA, 1:200 in blocking 
buffer). Blots were washed three times for 15 min in 
PBS-T. As a secondary antibody, horseradish peroxi-
dase-conjugated mouse-anti-rabbit IgG in a dilution of 
1 : 2000 (Santa Cruz Biotechnology Inc., CA) was used. 
After the second washing procedure, CD26 molecule 
(110 kDa) was detected by chemiluminescent Amer-
sham ECL-plus Western blotting detection reagents 
(Amersham, Little Chalfont, UK), which enabled visu-
alization of bends after exposure to photosensitive films 
(AGFA Ortho CP-G plus). Equal total protein loading 
was ensured with use of the primary mouse ß-actin 
antibody (Chemicon International, USA), in a dilution 
of 1 : 40000, and secondary horseradish peroxidase-
conjugated goat-anti-mouse IgG in a dilution of 1 : 2000 
(Santa Cruz Biotechnology Inc., CA).  
 
Statistical Analyses 
Results are expressed as mean ± standard deviation. 
Statistical comparisons were made using STATISTICA 
version 8.0 (StatSoft Inc., TULSA, USA). Testing dif-
ferences between groups has been performed using 
ANOVA and post-hoc Scheffe test. The level of P<0.05 
was defined as statistically significant. 
 
RESULTS AND DISCUSSION  
TNBS-induced colitis in mice is an experimental model 
of IBD which shares many similarities with CD in hu-
mans at molecular levels and in clinical manifestations 
of disease and therefore represents a valuable tool in 
IBD research.7 Macroscopic signs of inflammation char-
acteristic for TNBS-induced colitis comprise marked 
oedema and mucosal thickening, which are accompa-
nied by increased colon weight.18 Results of our study 
are in agreement with these observations. The presence 
of an accentuated oedema in the colon was determined, 
with marked inflammatory changes that were most 
conspicuous the second day following TNBS-ethanol 
administration. Therefore, the second day after colitis 
induction was classified as acute phase of colitis, which 
is in agreement with previously reported findings.7 
Shortening and thickening of the colon was also ob-
served in mice which received TNBS-ethanol solution. 
Intrarectal application of TNBS-ethanol solution in mice 
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induces a transmural, granulomatous inflammation with 
infiltration of inflammatory cells mainly located in the 
distal part of the colon.7 Histopathological changes 
observed in colon tissue sections of both wild type and 
CD26 deficient mice confirmed the presence of inflam-
matory processes and accomplishment of colitis induc-
tion. It should be emphasized that to date, no TNBS-
induced colitis in CD26 deficient mice was described in 
available literature to our knowledge, and scarce results 
are published regarding investigation using this mice 
strain. 
Like macroscopic changes, microscopic changes 
were also most prominent in the acute phase of colitis. 
Patohystological analyses confirmed the presence of 
inflammatory changes in the colon of mice that received 
TNBS-ethanol solution. Partly necrotic mucosa, largely 
penetrated with granulocytes and disintegrated leuko-
cytes is visible in Figure 1. Inflammatory changes did 
not overtake the entire mucosa, in most analyzed colon 
samples a part of the colonic mucosa was preserved 
with physiological appearance of crypts. Analyses of 
larger number of colonic sections revealed differences 
in inflammatory manifestations among two analyzed 
mice strains. In CD26 deficient mice, ulcerations were 
mostly localized in a certain part of the mucosal surface, 
but in a number of mice, a transmural inflammation was 
observed (Figure 2A). On the other hand, no transmural 
inflammations were observed in wild type animals, but 
inflammatory changes affected the entire colonic cir-
cumference with very little or no areas of preserved 
mucosa (Figure 2B). 
Results of histomorphometrical analyses also con-
firmed the presence of inflammatory changes in both 
mice strains which received TNBS-ethanol solution. 
Number of crypts of Lieberkühn per mm of mucosa, and 
their depth and width for different groups of both mice 
strains at given days of experiment were measured (data 
not shown). Statistical analyses of obtained results 
among both control groups of animals did not reveal 
statistically significant changes in observed parameters, 
nor at different days of sacrifice. In both mice strains 
with induced colitis, a statistically significant (P < 0.05) 
decrease in number of crypts of Lieberkühn per mm of 
mucosa was observed in the acute phase of colitis. 
Changes persisted even during tissue healing in CD26 
deficient mice. The width of crypts of Lieberkühn was 
increased in the acute phase of colitis in both mice 
strains, but it took longer to achieve physiological val-
ues in wild type mice. Furthermore, the depth of crypts 
of Lieberkühn was decreased in acute colitis in both 
mice strains. All those changes represent consequences 
of inflammatory processes in the colon which include 
mucosa thickening and formation of oedema due to 
TNBS-ethanol-induced tissue damage. 
Analyses of DPP IV/CD26 activity and protein 
expression were performed at systemic and local levels, 
in the serum and among the gut-brain axis respectively, 
in wild type mice. Since we wanted to evaluate whether 
in conditions of DPP IV/CD26 deficiency other DPP 
IV/CD26-like enzymes could partially take over its 
enzymatic function, DPP IV/CD26-like systemic and 
local activities were determined in CD26 deficient mice. 
Results of serum DPP IV/CD26 activity in wild type 
mice with induced colitis compared to control groups 
are presented on Figure 3A. A statistically significant 
decrease (P < 0.05) in serum DPP IV/CD26 activity was 
observed starting in the acute phase of colitis and 
achieving physiological values after disease healing. 
Our results accord with previously published results that 
included determination of serum DPP IV/CD26 activity 
in patients with IBD and other chronic diseases.19–22 
Figure 2. Strain-characteristic inflammatory changes in distal
colon of CD26–/– (A) and C57BL/6 mice (B) in the acute
phase of colitis, two days after administration of TNBS-
ethanol solution. Colon sections (2 μm) were stained with
hematoxylin and eosin and examined for pathologic changes.
The original magnification was 4 x. 
Figure 1. Inflammatory changes in distal colon of C57BL/6
mice in the acute phase of colitis, two days after administra-
tion of TNBS-ethanol solution. Colon sections (2 μm) were
stained with hematoxylin and eosin and examined for patho-
logic changes. The arrow indicates partly necrotic mucosa,
largely penetrated with granulocytes and disintegrated leuko-
cytes. The original magnification was 20 x. 
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Therefore, a clinical relevance of serum DPP IV/CD26 
activity as a marker of disease severity in IBD was pro-
posed.21 Its role in inflammatory events includes degra-
dation of biologically active substrates which have a 
crucial role in inflammation. Our results are in accord-
ance with the observation that serum DPP IV/CD26 
activity correlates inversely with disease severity in 
patients with IBD.21  
In order to evaluate changes in serum DPP 
IV/CD26-like activities during colitis development and 
healing, CD26 deficient mice were analyzed. Results of 
our study show that CD26 deficient mice express ap-
proximately 10 % of total serum DPP IV/CD26 activity 
detected in wild type mice. Figure 3B shows results of 
serum DPP IV/CD26-like activity in CD26 deficient 
mice with induced colitis compared to their control 
groups. It could be seen that no statistically significantly 
differences were found in serum DPP IV/CD26-like 
activity between groups of CD26 deficient animals with 
colitis and control animals. Therefore, the significance 
of DPP IV/CD26 over DPP IV/CD26-like serum activi-
ty is proposed.  
In the last decade, growing scientific evidence 
emphasizes neuroimmunomodulation as an important 
factor in the occurrence of inflammation.23 Due to the 
causal connection between central and enteric nervous 
system, the term gut-brain axis has been proposed.5 DPP 
IV/CD26 has previously been proven to play an im-
portant role in metabolism of important bioactive neuro- 
and immunopeptides, as well as in the costimulation of 
immune cells.11 Given its localization in the nervous 
system and among the digestive tract, likewise on the 
surface of important inflammatory cells,24 our aim was 
to investigate changes in DPP IV/CD26 activity and 
protein expression at sight of inflammation and reveal if 
those changes reflect on examined parameters in the 
brain. 
Figure 3. Serum DPP IV/CD26 activity in C57BL/6 mice (A)
and serum DPP IV/CD26-like activity in CD26–/– mice (B) 
during colitis development and resolution compared to control
group. Statistically significantly different values (a) compared 
to control group (P < 0.05). 0 – control group, physiological 
condition; 2, 7, 15, 30 days after administration of TNBS-
ethanol solution (colitis group) or ethanol solution (control
group). 
 
Figure 4. DPP IV/CD26 activity in colon of C57BL/6 mice
(A) and DPP IV/CD26-like activity in colon of CD26–/– mice
(C). CD26 protein expression in colon of C57BL/6 mice dur-
ing colitis development and resolution compared to control
group (B). Statistically significantly different values (a) com-
pared to control group (P < 0.05). 0 – control group, physio-
logical condition; 2, 7, 15, 30 days after administration of
TNBS-ethanol solution (colitis group) or ethanol solution
(control group). 
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Our results showed an accentuated decrease in 
DPP IV/CD26 activity in the inflamed colon in wild 
type animals compared to their control groups (Figure 
4A). On the other hand, Western blotting technique 
revealed an increased CD26 protein expression in the 
acute phase of disease, as shown on Figure 4B. This 
phenomenon could, besides a regulatory mechanism at 
the enzymatic level, also be partially explained as a 
compensatory mechanism, since a part of the decreased 
DPP IV/CD26 activity in the colon of wild type mice is 
a consequence of severe mucosal damage induced by 
TNBS-ethanol application. Therefore, enhanced CD26 
protein expression in the acute phase of disease could 
represent an attempt to accomplish a compensatory role 
due to damaged DPP IV/CD26 conformation and im-
proper enzyme activity in inflamed tissue. An enhanced 
DPP IV/CD26 mRNA production has previously been 
shown under inflammatory environment.25 Consequent-
ly, a higher CD26 protein expression could be expected 
in inflammation. Our results are in agreement with pre-
viously reported observations regarding enhanced CD26 
protein production in inflamed tissue. 
Investigations on DPP IV/CD26-like activity in 
the colon of CD26 deficient mice shown that, in physio-
logical conditions, CD26 deficient mice express less 
than 2 % of total DPP IV/CD26 activity detected in the 
colon of wild type mice. Statistically significantly 
(P < 0.05) decreased DPP IV/CD26 activity in inflamed 
colon homogenates was also found in CD26 deficient 
mice compared to their controls (Figure 4C). However, 
this could also partially be a consequence of tissue dam-
age and not only an intrinsic regulation mechanism 
which downregulates the activity of DPP IV/CD26-like 
enzymes in inflammatory processes. 
Interesting results were found when analyzing 
DPP IV/CD26 activity in brain homogenates during 
colitis development and resolution in wild type mice. It 
was found that DPP IV/CD26 activity in brain is statis-
tically significantly decreased (P < 0.05) in the acute 
phase of colitis compared to control groups (Figure 5A), 
while the activity of DPP IV/CD26-like enzymes does 
not change (Figure 5C). On the other hand, CD26 pro-
tein expression, as confirmed by Western blot technique 
(Figure 5B) remains constant. A possible explanation of 
this phenomenon could be a regulatory mechanism 
which control DPP IV/CD26 activity in brain, inde-
pendently of its protein expression. Likewise, since 
there is no local inflammation in the brain which could 
destroy DPP IV/CD26 enzymatic function like in the 
inflamed colon, there is no need for a potential compen-
satory mechanism which would try to compensate lower 
DPP IV/CD26 activity by its higher protein expression. 
Therefore, lower DPP IV/CD26 activity and its un-
changed protein expression in the brain most probably 
represents an intrinsic regulatory mechanism at the 
enzymatic level. 
Moreover, results of this study indicate that 
changes which occur during inflammatory processes at 
local level, in the colon, exhibit a reflection on investi-
gated parameters in the central nervous system. There-
fore, a decreased DPP IV/CD26 activity in the brain is 
most probably causally connected with its changes in 
the colon during inflammatory events. Hence, our re-
sults indicate the importance of the gut-brain axis in the 
pathogenesis of IBD. This study reveals new data about 
DPP IV/CD26 activity and protein expression in a mod-
el of Crohn-like colitis in mice. Likewise, due to very 
little available results of colitis investigation under con-
ditions of CD26 deficiency, our study gives new in-
sights in inflammatory manifestations induced by 
TNBS-ethanol administration in CD26 deficient mice. 
 
Figure 5. DPP IV/CD26 activity in brain of C57BL/6 mice
(A) and DPP IV/CD26-like activity in brain of CD26-/- mice
(C). CD26 protein expression in brain of C57BL/6 mice dur-
ing colitis development and resolution compared to control
group (B). Statistically significantly different values (a) com-
pared to control group (P < 0.05). 0 – control group, physio-
logical condition; 2, 7, 15, 30 days after administration of
TNBS-ethanol solution (colitis group) or ethanol solution
(control group). 
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Inhibition of DPP IV/CD26 has been proposed as 
potential therapy for chronic inflammatory diseases.26 
This hypothesis is supported by higher values of anti-
inflammatory cytokines obtained in CD26 deficient 
mice.27 Furthermore, it has recently been shown that 
inhibition of DPP IV/CD26 partially ameliorates colitis 
in mice.28 IBD is characterized by imbalances in innate 
and acquired immune response, where two dysregulated 
T cell subsets are crucial: activated effector T cells and 
regulatory T cells. They are characterized by a strong 
expression of DPP IV/CD26, which has been confirmed 
to play a significant role in the control of immune acti-
vation and in regulating cellular communication by 
hydrolyzing bioactive polypeptides.29 Positive results in 
the regulation of immune and non-immune processes in 
IBD have been proved in vitro as well in vivo with DPP 
IV/CD26 and alanyl-aminopeptidase inhibitors.30 
Nevertheless, results of our study showed that 
CD26 deficient mice are not protected from chemically 
induced Crohn-like colitis, but exhibit some differences 
in histological damage compared to wild type mice. 
Otherwise, CD26 deficient mice show a normal pheno-
type and behavior as wild type mice, but are known to 
posses and enhanced insulin secretion and improved 
glucose tolerance.14 This knowledge lead to develop-
ment of DPP IV/CD26 inhibitors in the therapy of dia-
betes mellitus type II which are already in clinical 
use.31–33 However, further studies should be done in 
order to test if DPP IV/CD26 inhibition could be an 
acceptable therapeutic approach in chronic inflammato-
ry disease alleviation, as new drug candidates for the 
treatment of diseases associated with an imbalanced T 
cell response.  
 
CONCLUSIONS 
This study reveals new data about DPP IV/CD26 activi-
ty and protein expression in a model of TNBS (Crohn-
like) colitis in mice. Due to meager available results of 
colitis investigation under conditions of CD26 deficien-
cy, we established a TNBS-ethanol induced colitis in 
CD26 deficient mice. Our study gives new insights in 
Crohn-like colitis inflammatory manifestations in CD26 
deficient mice. Results of our study showed that CD26 
deficient mice are not protected from chemically in-
duced Crohn-like colitis, but show specificity in histo-
logical damage compared to wild type mice. A de-
creased DPP IV/CD26 activity was found in serum, 
colon and brain in C57BL/6 mice with colitis, while 
DPP IV/CD26-like activity is decreased only in colon of 
CD26 deficient mice. An enhanced protein expression 
of CD26 molecule was found in colon of wild type mice 
in the acute phase of colitis. It was noticed that changes 
occurring during inflammatory processes in the colon, 
reflect on investigated parameters in the central nervous 
system. Therefore, our results indicate the importance of 
the gut-brain axis in the pathogenesis of IBD.  
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